Beam Therapeutics Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net income was USD 142.8 million compared to net loss of USD 38.35 million a year ago. Basic earnings per share from continuing operations was USD 1.77 compared to basic loss per share from continuing operations of USD 0.54 a year ago. Diluted earnings per share from continuing operations was USD 1.73 compared to diluted loss per share from continuing operations of USD 0.54 a year ago.
For the full year, net loss was USD 132.53 million compared to USD 289.09 million a year ago. Basic loss per share from continuing operations was USD 1.72 compared to USD 4.13 a year ago. Diluted loss per share from continuing operations was USD 1.72 compared to USD 4.13 a year ago.